Outlook Therapeutics, Inc.
NASDAQ:OTLKBiotechnology
Healthcare
$0.40 -5.76%
-$0.10 today
- Market cap
- $97.62M
- Beta
- 0.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$0.74
52W Low $0.16High $3.39
Volume 6.81M
Average 17.46M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$51.83M
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$44.98M
FY 2025 · Annual
-25.4% YoYCash Flow Statement
USD
Metric | FY 2021 Sep 2021 | FY 2022 Sep 2022 | FY 2023 Sep 2023 | FY 2024 Sep 2024 | FY 2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | (53.16M) | (66.05M) | (58.98M) | (75.37M) | (62.42M) |
| Depreciation & Amortization | 262.14K | 204.69K | 44.19K | 113.86K | 117.05K |
| Deferred Income Tax | 498.49K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.89M | 7.71M | 5.55M | 5.39M | 8.9M |
| Change in Working Capital | (7.08M) | (1.68M) | 4.75M | (3.02M) | 4.86M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (1.49M) |
| Inventory | 0 | 0 | 0 | 0 | (3.34M) |
| Accounts Payables | (198.47K) | 1.3M | 3.08M | 1.39M | 1.67M |
| Other Working Capital | (6.88M) | (2.98M) | 1.67M | (4.41M) | 8.02M |
| Other Non-Cash Items | 341.55K | 3.15M | 5.66M | 4.09M | 1.58T |
| Operating Cash Flow | (54.25M) | (56.67M) | (42.97M) | (68.79M) | (51.83M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | (3) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 6.31M | (2.32M) | 19.77M | (4.27K) | (3.04M) |
| Common Stock Issued | 46.3M | 62.31M | 30.02M | 60.33M | 48.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.59M | (394.15K) | (823.89K) | 0 | 44.98T |
| Financing Cash Flow | 56.19M | 59.59M | 48.97M | 60.33M | 44.98M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.94M | 2.92M | 6M | (8.46M) | (6.84M) |
| Free Cash Flow | (54.25M) | (56.67M) | (42.97M) | (68.79M) | (51.83M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$62.4M
+ D&A$117.1K
+ Stock-Based Comp$8.9M
+ Deferred Tax$0
+ Working Capital$4.9M
+ Other Non-Cash$1.6T
= Operating Cash Flow-$51.8M
- Capex-$3
= Free Cash Flow-$51.8M
Analysis
FY2025 free cash flow is -$51.8M. FCF conversion is 83.0% of net income. Operating cash flow was -$51.8M, with capex of -$3. The largest bridge item is Other Non-Cash at $1.6T.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Oct 13, 2026 | |
| 8-K | Current report | Sep 30, 2026 | |
| 8-K | Current report | Sep 18, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 2, 2026 | |
| 3 | Initial statement of beneficial ownership | Sep 2, 2026 |
Does OTLK generate free cash flow?
Outlook Therapeutics, Inc. (OTLK) generated -$51.83M of free cash flow in fiscal 2025.
How much operating cash flow does OTLK produce?
Operating cash flow was -$51.83M, before capital expenditures of $3.00.
Continue the stock analysis
Jump to another research area for this company.